Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9154467 | American Heart Journal | 2005 | 7 Pages |
Abstract
Although definitive conclusions cannot be made as a result of the small sample size and premature study termination, facilitated PCI with eptifibatide + reduced-dose tenecteplase was associated with improved angiographic flow patterns, increases in adverse clinical outcomes, and higher bleeding rates compared with eptifibatide + placebo administered before primary PCI for STEMI.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
The ADVANCE MI Investigators The ADVANCE MI Investigators,